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Abstract
Background: Melanoma vaccines have not been optimized. Adjuvants are added to activate dendritic cells (DCs)
and to induce a favourable immunologic milieu, however, little is known about their cellular and molecular effects
in human skin. We hypothesized that a vaccine in incomplete Freund’s adjuvant (IFA) would increase dermal Th1
and Tc1-lymphocytes and mature DCs, but that repeated vaccination may increase regulatory cells.
Methods: During and after 6 weekly immunizations with a multipeptide vaccine, immunization sites were biopsied
at weeks 0, 1, 3, 7, or 12. In 36 participants, we enumerated DCs and lymphocyte subsets by
immunohistochemistry and characterized their location within skin compartments.
Results: Mature DCs aggregated with lymphocytes around superficial vessels, however, immature DCs were
randomly distributed. Over time, there was no change in mature DCs. Increases in T and B-cells were noted. Th2
cells outnumbered Th1 lymphocytes after 1 vaccine 6.6:1. Eosinophils and FoxP3+ cells accumulated, especially after
3 vaccinations, the former cell population most abundantly in deeper layers.
Conclusions: A multipeptide/IFA vaccine may induce a Th2-dominant microenvironment, which is reversed with
repeat vaccination. However, repeat vaccination may increase FoxP3+T-cells and eosinophils. These data suggest
multiple opportunities to optimize vaccine regimens and potential endpoints for monitoring the effects of new
adjuvants.
Trail Registration: ClinicalTrials.gov Identifier: NCT00705640
Background
Existing therapies for advanced melanoma are rarely
curative. Even recent exciting data with a novel specific
B-raf kinase inhibitor are limited by the transience of
the clinical responses [1]. On the other hand, a large
percentage of complete responses to immune therapy
with interleukin-2 have been durable for over a decade
[2], and other new immune therapies have been asso-
ciated with long-lasting complete responses [3,4]. There
is a strong rationale for the development of immune
therapies specifically targeting melanoma antigens.
These vaccines may be employed in the adjuvant setting,
to treat patients who are at high risk of recurrence but
are clinically free of disease. The failure of several cell-
based melanoma vaccine Phase III trials has highlighted
the need to optimize their efficacy [5-9]. Vaccination
with purified defined antigens has the advantage of
enabling the assessment of immune responses to the
antigens, as well as avoiding possible toleragenic or
immunosuppressive components of cell-based vaccines.
Recent data from a phase III randomized trial demon-
strate the clinical benefits of combining a peptide anti-
gen vaccine with high-dose IL-2 therapy [10]. Despite its
benefits, however, the majority of patients treated with
this combination showed disease progression. Peripheral
blood T-cell responses to most melanoma vaccines are
often transient and usually of lower magnitude than
responses to viral vaccines[11]. Thus, there is evidence
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for the value of melanoma vaccines incorporating
defined antigen and a need to improve their ability to
induce T cell responses.
A variety of adjuvants, systemic cytokines, antigen for-
mulations, doses, routes of delivery and frequency of
vaccinations have been studied. Arguably, there are hun-
dreds or thousands of permutations of these variables,
only a few of which have been tested formally for their
superiority over others [12-14]. If survival or systemic
immune response is the study endpoint, trials testing
the superiority of one approach over another may
require over a hundred patients. Alternative endpoints
that permit the rapid assessment of the biologic effects
of adjuvants, cytokines, antigen formulation, frequencies
and dose in human subjects are needed. We have found
that evaluating the immune responses in the vaccine-
draining node can be helpful in increasing the power of
small studies to identify differences in vaccine immuno-
genicity, or to reinforce findings from the peripheral
blood [15,16]. This approach requires substantial
resources, as well as a dedicated surgeon, and is not
widely applicable. On the other hand, we have found
that the inflammatory infiltrate at cutaneous vaccination
sites includes superficial aggregates of mature dendritic
cells and lymphocytes surrounding PNAd+ vessels that
resemble the high endothelial venules of lymph nodes
(Harris RC et al.: Histology and immunohistology of
cutaneous immune cell aggregates after injection of mel-
anoma peptide vaccines and their adjuvant, submitted).
Lymphocytes in these aggregates are actively proliferat-
ing, suggesting that they may be participating in a local
immune response, challenging the classic conception
that the only function of the vaccination site microen-
vironment is to provide antigen and dendritic cells to
the draining nodes. Our experience with multipeptide
vaccines in an IFA has been that we induce immune
responses to one or more peptides in most patients, but
many of those responses are transient [17,18]. Thus, we
hypothesize that negative regulators of Tc1/Th1 T cell
function may accumulate or be up-regulated in the vac-
cination site microenvironment over time. We have
initiated a series of studies to explore this general
hypothesis, and anticipate that this project will guide
future clinical trials to optimize vaccine efficacy.
In the present study, we report observations about the
inflammatory infiltrate induced by incomplete Freund’s
adjuvant, with or without peptide, in a clinical trial of a
melanoma vaccine. We show data assessing whether: (a)
1-3 injections would induce perivascular dermal lym-
phoid aggregates, with accumulation of mature dendritic
cells; and, (b) extended immunization (4-6 vaccines)
would induce negative immune regulatory processes in
the vaccination site microenvironment. This initial
report focuses on direct evaluation of the cellular
components and histomorphometric organization of
cells in the vaccination site microenvironment. Insights
gained regarding the balance of these factors over time
may identify opportunities for modulation of the immu-
nization microenvironment and for improving vaccine
immunogenicity and clinical outcome.
Methods
Registration site and number: University of Virginia,
NCT00705640 (ClinicalTrials.gov identifier), also
referred to as the Mel48 trial
Protocol
Patients with resected AJCC stage IIB-IV melanoma aris-
ing from cutaneous, mucosal, ocular, or unknown pri-
mary sites were eligible. Inclusion criteria included:
expression of HLA-A1, A2, A3, or A11 (~85% of patients
screened, data not shown); age 18 years and above;
ECOG performance status 0-1; adequate liver and renal
function; and ability to give informed consent. Exclusion
criteria included: pregnancy; cytotoxic chemotherapy,
interferon, or radiation within the preceding 4 weeks;
known or suspected allergies to vaccine components;
multiple brain metastases; and use of steroids or Class
III-IV heart disease. Patients were studied following
informed consent, as well as Institutional Review Board
(IRB/HSR #13498) and FDA approval (BB-IND #12191).
Design and sample size
This is a companion tissue study, which is part of an
open-label pilot study consisting of two treatment groups
of patients with melanoma who have been immunized
with a melanoma vaccine, each divided into 5 subgroups,
to determine evaluation time points for a biopsy examin-
ing the injection site microenvironment. Study subjects
were randomly assigned to one of ten possible arms (2
[types of replicate site injections] × 5 [biopsy times] =
10). In the analysis for this report, the type of injection at
replicate vaccination sites was not considered.
The current report is not an assessment of the pri-
mary protocol objectives, as follow-up and analyses are
not yet complete, but an assessment of the tissue speci-
mens by 1) location within skin compartments and 2)
differences over time. Initial sample size calculations
were based upon a two factor design (treatment and
time) which indicated that 4 subjects per cell should be
adequate to determine patterns of interest. The design
maintained a target of 80% power for the hypothesized
effect sizes. The maximum accrual to the study was esti-
mated to be 44 subjects in order to accrue the required
36 eligible subjects to meet the study objectives. The
study was designed with an interim analysis after
approximately 75% of eligible subjects for whom an eva-
luable biopsy was obtained. Results in the current report
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were not predefined and were noted at the time of the
interim analysis. Therefore, the interim analysis signifi-
cance level of 0.001 was used to guide interpretation of
subsequent results.
Assignment
All patients were administered MELITAC 12.1 peptide
vaccine emulsified in Montanide ISA-51VG, modified
incomplete Freund’s adjuvant. MELITAC 12.1 is a pre-
viously reported vaccine regimen that includes 12 mela-
noma associated peptides restricted by Class I MHC
molecules plus a tetanus helper peptide [19]. Concurrent
with the primary vaccinations, participants received a
second set of injections in a replicate vaccination site.
Participants were evaluated in each of two groups, one
receiving MELITAC 12.1 plus IFA at the replicate vacci-
nation site, and one receiving IFA only at the replicate
vaccination site. Within each study group, participants
had a surgical biopsy of the replicate site performed at
one of five possible times: day 1 (no vaccine), day 8 (1
week after the first vaccine/week 1), day 22 (1 week
after the third vaccine/week 3), day 50 (1 week after the
sixth vaccine/week 6), or day 85 (6 weeks after the sixth
vaccine/6 weeks out). These were denoted subgroups A,
B, C, D, and E respectively. The biopsy was an elliptical
excision (width 2 cm, length 4-6 cm) of the replicate
immunization site, performed under local anesthesia in
the clinic.
Masking
The dermatopathologists (JTS and JWP) were unaware
of the study group during the primary assessments.
Participant flow
This report is based upon data from 36 evaluable parti-
cipants. Multiple biological markers were analyzed on
the biopsy samples of all 36 participants.
Follow-up
Participant disease progression and survival will be
closely monitored.
Quantification and statistical analysis
All data was collected at the University of Virginia
Health System. For each of the 10 endpoints (CD3,
CD4, CD8, CD20, Tbet, GATA3, CD1a, CD83, FoxP3
and eosinophils), and within each skin layer, the average
number of counts from ten continuous high powered
fields were calculated for each study subject. For each
outcome, mean HPF levels were calculated for each skin
layer and overall. Ratios of the means between certain
outcomes of interest were calculated.
The analysis of each endpoint was performed indivi-
dually using the method of generalized estimating
equations (GEE) [20]. This model approach assessed
relationships between cell counts (per endpoint) and
two factors of interest, time of biopsy (5 levels) and
layer of skin (3 levels), while assuming the absence of
interaction between the factors. The response distribu-
tion was specified as negative binomial and the link
function used was the natural logarithm function. Cor-
relation between intra-subject counts obtained from dif-
ferent skin layers was estimated with a compound
symmetric structure. Wald tests were used to determine
the statistical significance of comparisons of interest,
namely, differences of infiltrate counts by time point
and by skin layer levels. The statistical analysis was per-
formed using the GENMOD procedure in SAS 9.1.3
(SAS Institute, Cary, NC). All tests were performed with
a = 0.001. This restrictive guideline was used in
response to the issue of multiple comparisons.
Histological and immunohistochemistry methods: Par-
affin-embedded tissue sections were cut and deparaffi-
nised, and heat-based antigen retrieval was performed.
A peroxidase-based enzyme system (DAB) was used
according to the manufacturer’s directions (Vector, Bur-
lingame, CA). The following primary antibodies were
used: CD3 (Vector, Burlingame, CA-1:150), CD4 (Vec-
tor, Burlingame, CA-1:40), CD8 (DakoCytomation, Den-
mark-1:50), CD20 (Dako, Denmark-1:200), Tbet (Santa
Cruz, CA -1:20), GATA3 (BD Pharmingen, San Jose,
CA-1:100), FoxP3 (clone PCH101, eBioscience, San
Diego, CA-1:125), CD1a (Dako, Denmark-1:50), CD83
(Leica, Wetzlar, Germany-1:20). Specificity was demon-
strated by the absence of staining products using non-
immune corresponding immunoglobulin. Human lymph
nodes were used as positive controls. Quantification of
superficial dermal, deep dermal and subcutaneous end-
points was performed by capturing images of hematoxy-
lin/eosin and immunohistochemical sections using an
Olympus BX51 microscope and Olympus DP71 camera
(Olympus, Center Valley, PA)
Results
Eligibility review
This report summarizes histologic data from 36 evalu-
able patients enrolled between June 5, 2008 and May 5,
2009 on the Mel48 clinical trial (Figure 1). Overall, 72%
were male, and median age was 53 years. Median ages
across study time points were (57, 60, 52, 43, and 55 for
groups A through E, respectively). All patients were
Caucasian, none were Hispanic.
Histomorphology: The histomorphologic spectrum
demonstrates evolution of a transient, prominent
lymphohistiocytic infiltrate
Histomorphometric analysis of the immunization site
microenvironment (ISME) was first performed by
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microscopic evaluation of histologic sections of skin at
the vaccine sites, collected at one of 5 time points from
each of the 36 patients biopsied in this study population.
Representative images of the superficial and deep dermis
and subcutis are shown in Figure 2. Prior to the first
vaccine (time point A, Figure 2), few lymphocytes were
evident in the superficial dermis, surrounding the super-
ficial vascular plexus, which represents normal skin.
After the first vaccine, however, increased numbers of
inflammatory cells were evident, not only around the
superficial vessels, but also around the deep dermal vas-
culature and eccrine coils. The inflammatory infiltrate
increased and filled nearly the entire dermis and subcu-
tis following the third and sixth vaccines. Six weeks past
the last vaccine (time point E, Figure 2), the cellular
infiltrate receded from the dermis and subcutis and
mainly surrounded superficial and deep dermal blood
vessels and adnexal structures.
After three vaccines, foreign-body type giant cells were
observed. In the subcutis, the infiltrates assumed a
Figure 1 Mel48 Protocol schema. All patients were vaccinated 6 times at the primary vaccination site, on weeks 0, 1, 2, 4, 5, and 6. At the
replicate vaccination sites, the number of vaccines given depended on when the vaccination site was biopsied, as shown schematically here. V
= vaccination, vertical black bar = vaccination site biopsy.
Figure 2 Lymphohistiocytic infiltrate increasing over time. H&E stained histologic sections of replicate vaccination site, representative for
each time point (A: no vaccine; B: 1 week after 1st vaccine; C: 1 week after 3rd vaccine; D: 1 week after 6th vaccine; E: 6 weeks after 6th vaccine).
Top panel: The three compartments: superficial papillary dermis; middle panel: deep dermis, lower panel: subcutis. Note the significant increase
of the inflammatory infiltrate between the first (B) and third (C) vaccination in all compartments. Bar = 100 μm.
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configuration reminiscent of combined septal and lobu-
lar panniculitis. Striking tissue eosinophilia was noted in
the deep layer of two-thirds of cases, while at least mod-
erate numbers of eosinophils were observed in all cases
at time point C or later (Figure 3A and 3B). Areas of fat
necrosis were also observed (Figure 3C). Large, spherical
“empty spaces”, demarcated by a prominent granuloma-
tous reaction, were evident in the subcutis. These spaces
represent adjuvant deposits, which were dissolved dur-
ing tissue processing (Figure 3D).
Similar histomorphologic and immunophenotypic
findings were observed in arms 1 and 2 (IFA without or
with peptide antigens, respectively, data not shown).
Characterization of the lymphocytes infiltrating the ISME
To further characterize the cellular components of the
infiltrate, a series of immunohistochemical (IHC) studies
were performed. The lymphocytic infiltrates had a domi-
nant T-cell (CD3+) component, with a smaller CD20+
B-cell component (Figure 4). CD8+ T cells were more
dispersed, whereas CD4+ T cells were frequently
encountered in clusters, especially around blood vessels
(perivascular T-cell zone - CD4 population not shown).
CD20+ B-cells occured singly or in clusters and were
sometimes intimately associated with the perivascular
T-cell zones.
The number of T cells (CD3+) increased from a mean
of 5.3 per high-power field (HPF) prevaccine to 17.6 at
time point B, with a further increase to 81.9 at week 3
(C), which represented a statistically significant increase
(p < 0.001 - all statistically significant findings reported
in this study have a p-value below 0.001, Figures 5 and 6
- figure 5 shows data of all 36 patient while figure 6 only
represents data of patients receiving both adjuvant and
peptide at the replicate vaccine site). The numbers
appeared stable through week 7 without any statistical
changes thereafter. The CD4+ and CD8+ T cell subsets
showed a statistical significant increase over the same
time course from time point A to B and to C, with a pla-
teau through time point E (Table 1). Mean numbers of
CD4+ T cells per hpf at those 5 time points were 3.8,
14.3, 57.8, 82.5 and 64.6, respectively, and for CD8+ T
cells were 2.8, 9.9, 41.2, 53.4 and 51.6. For CD3+ and
T-cell subsets CD4+ and CD8+, there were no consistent
differences between skin compartments (superficial,
papillary dermis, reticular dermis and subcutis) across
time points. B-cell numbers showed a trend towards
increasing slightly after one vaccine, but then increased
significantly by week 3 and 7 (p < 0.001, Figures 5 and 6).
T-helper subpopulations
A goal of peptide vaccines is to induce cytotoxic T cells,
which depend on Th1 help. Thus, we evaluated the Th1/
Figure 3 Pools of eosinophilis in the mid and deep layers following the third vaccine. (a) Numerous eosinophils are present in the
subcutis. Bar = 200 μm. (b) High-power view. Note the distinctive cytologic detail, including the bilobed nucleus in a round cell with numerous,
red cytoplasmic granules. Bar = 20 μm (c) Focal areas of fat necrosis (empty spaces of various sizes) are present. Bar = 200 μm (d) Note sites of
vaccine deposits (large, “empty” spaces walled off by macrophages. Bar = 100 μm.
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Th2 bias of the CD4+ T cells in the ISME by staining for
T-bet (Th1) and GATA-3 (Th2). The T-bet+ cells were
very rare pre-vaccine and did not change after 1 vaccine,
but increased significantly by week 3 (p < 0.001; C vs B;
Figures 7 and 8 - figure 7 shows data of all 36 patient
while figure 8 only represents data of patients receiving
both adjuvant and peptide at the replicate vaccine site).
In contrast, GATA3+ cells increased significantly over
time through weeks 1 and 3 (Figures 7 and 8). At week 1
and week 3, the GATA-3+/T-bet+ ratios were approxi-
mately 6.6:1 and 1:1, respectively (Table 2). There were
statistically significant layer effects for GATA3 showing
increased numbers in the deep layer that seem to have
been driven by later time points.
Eosinophils
Tissue eosinophilia was evaluated on H&E stained-sec-
tions. Eosinophils were absent or very rare pre-vaccine
(Figures 7 and 8) with no obvious change after the first
vaccine. However, there was a statistically significant
increase after three vaccines (Figures 7 and 8). There
was also a layer effect with the superficial compartment
showing significantly less eosinophils than the mid and
deep compartments.
FOXP3+ cell population
FoxP3+ cells were also enumerated: no obvious change
was noted after the first vaccination, but there was a
statistically significant increase after 3 vaccines (Figures
7 and 8). No overall differences were noted when the
superficial, mid and deep layers were compared.
Immature and mature dendritic cells
For mature (CD83+) DCs, there was a significant
decrease from the superficial to both the mid and deep
compartment. Mature (CD83+) DC were primarily
found in the superficial dermis (Figures 5 and 6) and
were clustered around superficial papillary dermal blood
vessels and adnexal structures. CD1a+ immature dendri-
tic cells were randomly distributed within the inflamma-
tory infiltrates; slightly increased numbers were seen in
the superficial compartment. No obvious changes were
noted in mature DCs over time (Figure 5 and 6).
Although statistically significant, the increase of imma-
ture (CD1a+) DCs over time was small.
Discussion
Prior studies have examined the histopathology of
delayed-type hypersensitivity (DTH) reactions, specifi-
cally following dendritic cell vaccines (Table 3). DTH
reactions are dominated by perivascular T-cell infiltrates
[21-24]. Time-course assessments have been lacking, as
they have only been reported for one patient in a small
study [25]. Prior studies did not examine primary vacci-
nation sites, and did not address the impact of adjuvants
Figure 4 Perivascular T-and B-cell infiltrate. (a) Prominent infiltrate of inflammatory cells composed of lymphocytes and macrophages. (b)
CD3+ T-cells (brown chromagen) cluster around blood vessel. (c) CD20+ B-cells (brown chromagen) group peripheral to the T-cell zone. Bar =
100 μm in a-c. (d) Double-staining for CD20+ B-cells (brown membranous stain) and CD8 (purple membranous stain). Counter-staining with
hematoxylin marks nuclei blue. Note the group of B-cells located distant from blood vessel and next to the perivascular zone. The latter is
composed of purple T-cells (we show the CD8+ population here) Bar = 50 μm.
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Figure 5 Boxplots by time and layer of all 36 study patients:
T cells, B cells, and dendritic cells. This figure illustrates T cell
(CD3), B cell (CD20), immature (CD1a) and mature (CD83) dendritic
cells in each of the three evaluated skin compartments (S =
superficial, M = mid and D = deep) over time (A = without vaccine;
B = 1 week after first vaccine; C = 1 week after third vaccine; D = 1
week after sixth vaccine; E = 6 weeks after last vaccine). The inner
box of the boxplot represents the 25th and 75th percentiles, while
the whiskers indicate the range. To facilitate data display, the square
roots of values were used with the y-axis labelled on the regular
scale.
Figure 6 Boxplots by time and layer of the “adjuvant and
peptide group": T cells, B cells, and dendritic cells. This figure
illustrates T cell (CD3), B cell (CD20), immature (CD1a) and mature
(CD83) dendritic cells in each of the three evaluated skin
compartments (S = superficial, M = mid and D = deep) over time
(A = without vaccine; B = 1 week after first vaccine; C = 1 week
after third vaccine; D = 1 week after sixth vaccine; E = 6 weeks after
last vaccine). The inner box of the boxplot represents the 25th and
75th percentiles, while the whiskers indicate the range. To facilitate
data display, the square roots of values were used with the y-axis
labelled on the regular scale.
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on recruiting immune cells for the induction of immune
responses. To our knowledge, a systematic histologic
and immunophenotypic characterization of vaccination
site microenvironments has not been previously
performed.
In the present study, we describe the character, mag-
nitude and time-course of the inflammatory infiltrate at
the vaccination site in patients receiving a multipeptide
vaccine in an incomplete Freund’s adjuvant, with quanti-
tative evaluation of superficial and deep dermis includ-
ing the subcutis. The cellular infiltrate consisted mainly
of T-lymphocytes and evolved to maximum intensity
after the third vaccination. Over a similar time frame,
cells accumulated that may have negative effects on
induction of Th1/Tc1 responses at the vaccination site.
These included evidence of an early Th2 dominant
microenvironment, with subsequent accumulation of
eosinophils and FoxP3+ T-cells. For all of these popula-
tions, we observed significant increases and subsequent
plateau after the third vaccination (time point C).
DCs are crucial for the initiation, regulation and pro-
gramming of antigen-specific responses [26,27]. Thus,
we also investigated their presence and location in the
vaccination site microenvironment. We found that
mature DCs clustered around the superficial vascular
plexus and periadnexal structures in association with
lymphocyte aggregates, suggesting their possible role in
priming T cells in this microenvironment. The deep
infiltrate contained very few mature DCs despite overall
high cellularity. Mature DCs maintained their physiolo-
gic distribution and did not significantly increase over
the time course of the vaccination protocol. Possible
explanations for the stagnant number of mature DCs
include immune regulation in the vaccination site
microenvironment or migration of mature DCs to drain-
ing lymph nodes. Although small, a statistically signifi-
cant increase of immature DCs was noted with multiple
vaccinations, reflecting a stimulatory effect on antigen-
presenting cells. Factors that enhance dendritic cell
maturation might be necessary and may have been miss-
ing. The combination of toll-like receptor agonists
(TLRs), anti-CD40, IFN-g and surfactant can augment
DC activation and subsequent cytotoxic T lymphocyte
Table 1 CD4+ and CD8+ T cells in ISME
TIME POINT NUMBER OF CELLS PER HPF CD4+:CD8+RATIO
CD4+ CD8+
A (pre-vaccine) 3.8 2.8 1.3
B (week 1) 14.3 9.9 1.4
C (week 3) 57.8 41.2 1.4
D (week 7) 82.5 53.4 1.5
E (6 weeks out) 64.6 51.6 1.3
Figure 8 Boxplots by time and layer of the “adjuvant and
peptide group": Th1, Th2, and Foxp3.This figure demonstrates
Th1 lymphocytes (Tbet+) and three negative regulators: Th2
lymphocytes (GATA3+), eosinophils and regulatory T-cells (FoxP3+) in
each of the three evaluated skin compartments (S = superficial, M =
mid and D = deep) over time (A = without vaccine; B = 1 week
after first vaccine; C = 1 week after third vaccine; D = 1 week after
sixth vaccine; E = 6 weeks after last vaccine). The inner box of the
boxplot represents the 25th and 75th percentiles, while the whiskers
indicate the range. To facilitate data display, the square roots of
values were used with the y-axis labelled on the regular scale.
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formation. Activation of DCs may be drastically
improved if two or more of these factors are added [28].
The present vaccination approach was designed to
induce cytotoxic T cells reactive to Class I MHC-asso-
ciated melanoma peptides, which classically depend on
support from Th1 helper T cells. In contrast, Th2 cells
support humoral immunity. The transcription factor T-
bet controls development of Th1, while GATA-3 directs
the Th2 lineage [29]. Therefore, our goal was to opti-
mize Th1-dominant responses to the vaccine, and a
tetanus helper peptide was included to expand Th1
helper T cells. In prior trials, this tetanus peptide did
induce Th1-dominant responses [30], and combinations
with Class I MHC associated peptides induced antigen-
specific cytotoxic T cells [15,18]. Thus, it was surprising
to find a significant increase of Th2 cells following the
first vaccine, leading to Th2 dominance (Table 2). This
finding likely has relevance for others using IFA adju-
vants, as it reflects an unbalanced early Th2 dominance
with the potential to compromise induction of Th1 and
Tc1 responses.
The current study also tested the effects of additional
vaccinations at the same location. Th1 cells culminated
after the 3rd vaccination and outnumbered Th2 helper
T-cells. One hypothesis is that Th1 cells rapidly emi-
grate from the vaccination site to populate the periph-
ery. However, we have rarely observed detectable T cell
responses in PBMC at just one week, and usually do not
observe them until at least 2-3 weeks [17,18]. Therefore,
we suggest that a minimum of three vaccines at the
same site are needed to trigger sufficient numbers of
Th1 helper lymphocytes with this vaccine and adjuvant
combination. Alternatively, the addition of TLR agonists
or other immune modulators may be explored as means
to induce an earlier Th1 dominant vaccination site
microenvironment.
In a Th2-rich infiltrate, a dominant cytokine produced
is IL-5, which is chemotactic for eosinophils [29]. There-
fore, the marked tissue eosinophilia observed after sev-
eral weeks is likely to be a longer-term manifestation of
the Th2 dominant early response and the persistence of
Th2 cells through week 12. We found a significant com-
partmental accentuation of eosinophils and Th2 cells,
Figure 7 Boxplots by time and layer of all 36 study patients:
Th1, Th2, and Foxp3 (Figure 7 demonstrates all 36 study
patients. Figure 8 only shows the “adjuvant and peptide
group”). This figure demonstrates Th1 lymphocytes (Tbet+) and
three negative regulators: Th2 lymphocytes (GATA3+), eosinophils
and regulatory T-cells (FoxP3+) in each of the three evaluated skin
compartments (S = superficial, M = mid and D = deep) over time
(A = without vaccine; B = 1 week after first vaccine; C = 1 week
after third vaccine; D = 1 week after sixth vaccine; E = 6 weeks after
last vaccine). The inner box of the boxplot represents the 25th and
75th percentiles, while the whiskers indicate the range. To facilitate
data display, the square roots of values were used with the y-axis
labelled on the regular scale.
Table 2 GATA3 and T-bet+ T cells in ISME





A (pre-vaccine) 1.3 0.5 2.8
B (week 1) 11.1 1.7 6.6
C (week 3) 35.4 37.9 0.9
D (week 7) 50.6 28.2 1.8
E (6 weeks out) 33.4 11.4 2.9
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primarily in the deep dermis and subcutaneous tissue. In
the superficial dermis, however, both Th2 lymphocytes
and eosinophils were less common, suggesting the pre-
sence of biologically relevant subset microenvironments
within the overall vaccination site. Given the observed
layer effect among compartments, the superficial papil-
lary dermis may have less of a Th2 effect, suggestive of
the possibility that this compartment may be a more
receptive environment for inducing a Th1/Tc1 response.
Regulatory T cells represent another mechanism by
which the immune response to vaccines may be limited.
FoxP3+ cells, identified by nuclear immunohistochemical
staining, corresponded well with the CD4+CD25high
FoxP3+ regulatory T cell populations identified by flow
cytometry using multi-antibody labeling [31]. FoxP3
expression can be found in activated non-regulatory T
cells [32-35]. However, high numbers of FoxP3+ cells
detected by immunohistochemistry in inflamed skin and
cancer tissue most likely represent regulatory T cells
[36,37]. In the present study, FoxP3+ cells increased fol-
lowing the third vaccination and persisted through week
12. The third vaccination again represents a critical time
point in the induction of negative regulators.
With respect to T lymphocyte subsets (CD4, CD8)
and B-cells (CD20), all populations increased signifi-
cantly, especially following the third vaccination. CD4:
CD8 ratios of 1:1 to 3:1 have been described in DTH
reaction sites following a recall injection [21,23,25] and
in classical DTH reactions [38]. Our ratios were at the
lower end of that range and lower than the physiologic
2:1 ratio in lymph nodes, with time point specific CD4:
CD8 ratios between 1.3:1 and 1.5:1 (Table 2). CD20+ B-
cell clusters were observed in juxtaposition to a CD3+
T-cell zone immediately surrounding the vascular
lumens (Figure 4). This zonation was reminiscent of
white pulp seen in the spleen. Overall, parallels between
the perivascular infiltrates and normal architecture of
lymph nodes and spleen are compelling. However, we
have not observed germinal center formation within the
B-cell clusters. Thus, not all features of tertiary lym-
phoid organs were present, as have been described in
certain chronic inflammatory disorders [39].
The early induction of Th2 cells in the vaccine micro-
environment suggests that adjuvants that could increase
Th1 cytokines may be valuable. In particular, IL-12 and
adjuvants that induce IL-12 production may be advanta-
geous immune modulators by enhancing Th1 polariza-
tion. Alternatively, interleukin-5 antibodies such as
mepalizumab might be useful if repeat vaccinations are
being performed at the same site and compartment, by
controlling tissue eosinophilia and directly interfering
with Th2 cytokine activity. This maneuver could poten-
tially reverse the IL-5 dominant milieu and tip the bal-
ance to a Th1-dominant environment.
Finally, these data suggest guidance regarding where
and how vaccinations should be performed. Changing to
a new vaccination site following the third injection (or
sooner) may minimize potential adverse effects observed
by repeat antigen injection into a microenvironment
populated with high numbers of regulatory T cells. How-
ever, such change also has the potential limitation of pla-
cing the antigenic peptide in an immunologically “un-
primed” environment. Short peptides have a brief half-
life in the presence of natural peptidases [11,40]. Thus,
peptide presentation in close proximity to mature DC’s
may be important. The use of longer peptides has been
suggested [41-43], as they may prolong antigen persis-
tence in the vaccine microenvironment and ensure pre-
sentation only by professional antigen-presenting cells.
The ideal vaccine protocol will maximize the contact
time between peptides and competent antigen presenting
cells by using an optimal peptide/adjuvant combination.
Many cancer vaccines are administered subcuta-
neously, even though intradermal antigen presentation
is an alternative. In this study, we focused on all com-
partments of the vaccination site, and found more
mature DCs present in the superficial papillary dermis
than in either the deep dermis or subcutis (mid and
deep compartments). Dense eosinophil populations
accumulated in the deeper layers relative to the superfi-
cial compartment. Thus, these data also suggest that
intradermal or even transdermal vaccines may be opti-
mal. Transdermal delivery models have been found to
be safe and effective for prophylactic vaccines [44-46].
Table 3 Histopathology of delayed-type hypersensitivity (DTH) reactions, specifically following dendritic cell vaccines*
Literature source CD4+ T cells CD8+ T cells CD20+ B cells CD56+ NK cells Distribution
Nestle, et al. (1998) [21] CD45R0+ & CD4+ NM NM NM perivascular
Bedrosian, et al. (2003) [24] Few numerous NM NM perivascular
de Vries, et al. (2005) [23] 50-70% 30-50% None NM perivascular
Nakai, et al. (2006) [22] Majority < CD4+ NM NM perivascular
Nakai (2009) [25] ≥ CD8++ ≤ CD4+ NM None Perivascular
NM = not mentioned
*Where reported, all were evaluated based on punch biopsies. The biopsy method was not described by Nestle (1998) and Nikai (2006).
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Recent studies exploring the advantages of nanoparticu-
late antigen systems in humans offer an interesting
alternative to intramuscular, dermal and subcutaneous
vaccination [47]. Using this approach, immunogenicity
could be induced using only one fifth of the antigen
dose required for intramuscular vaccination [48].
The histomorphologic and immunophenotypic obser-
vations regarding cellular infiltrates in the vaccine
microenvironment do not seem to be antigen-depen-
dent, since the observations for both the adjuvant +
peptide group (Figures 5 and 7) and the adjuvant only
group (Figures 6 and 8) were similar. However, a com-
prehensive analysis of the antigen-specific immune
response at the vaccination site and in the peripheral
blood is currently underway.
Conclusions
Despite the induction of CD4+ and CD8+ T-cell
responses in most patients when peptide vaccines are
administered in incomplete Freund’s adjuvant [19,49,50],
the immunization site microenvironment may not be
optimized for induction of Th1/Tc1 responses. This is
the first study of its kind that examines the immuniza-
tion site microenvironment. The relevance of its findings
will need to be tested, by correlation with systemic
immune response and clinical outcome, in future rando-
mized studies using different adjuvant systems and/or
immunogens. As part of the ongoing clinical trial that
provided the tissue samples for this study, circulating
immune responses to the vaccines will be measured and
reported when available, with the possibility that some
critical correlations may be elucidated.
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